ClinicalTrials.gg
Status unknownNCT04352465Updated Apr 29, 2020

Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients

A Phase 1/2 interventional study of Methotrexate and Methotrexate in COVID-19, sponsored by Azidus Brasil. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-29.

Sponsored by Azidus Brasil · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in COVID-19 by Azidus Brasil — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · Azidus Brasil.

Planned enrollment
8th of 10
42 · median 145
Started
2020
with 6 others
Phase 1/2
Only one
of the 10
Registered
5th of 10
by date

Among the 10 studies in COVID-19 by Azidus Brasil, this one is the 8th largest by planned enrollment, is one of 7 that started in 2020, is the only one in phase 1/2, and was the 5th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 10 studies in COVID-19 by Azidus Brasil is open now. Recruiting first, the newest first:

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in COVID-19 by Azidus Brasil, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.

Read the detailed description

Patients with acute lung injury caused by COVID-19 disease are experiencing an inflammatory reaction that can be harmful and worsen the severity of the clinical condition. Thus, the use of MTX-loaded nanoparticules in patients with acute lung injury secondary to COVID-19 aims to decrease the exacerbated inflammatory reaction leading to a decrease in cell damage caused by this inflammatory process in patients.

The study will be divided in 3 phases:

Phase A (n=4): IV administration of 20 mg of MTX-loaded nanoparticles. Four doses of Investigational Product (IP) will be administered, once per week. If patients show clinical improvement after 2nd or 3rd administration, the next phase will start.

Phase B (n=12): IV administration of 30 mg of MTX-loaded nanoparticles. Four doses of Investigational Product (IP) will be administered, once per week. If patients show clinical improvement after 2nd or 3rd administration, the next phase will start.

Fase C (n=26): IV administration of 40 mg of MTX-loaded nanoparticules. Four doses of Investigational Product (IP) will be administered, once per week.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. from patient or legal representative.
  2. Male or female, aged ≥ 18 years;
  3. Acute respiratory distress syndrome; with imminent risk of death, and with chest CT scan with pulmonary impairment greater than 50%;
  4. Confirmed or pending diagnosis of COVID-19.

Exclusion criteria

Exclusion Criteria:

  1. Pleural effusion > 150mL or ascites > 200mL;
  2. Chronic liver disease;
  3. and AST serum levels >= three times the upper limit of normality;
  4. Renal failure (dialysis)
  5. Multiple organ failure
  1. Concomitant use or use in the last 7 days of cell therapy with stem cells; 8. Any clinical or laboratory condition or comorbidity that, at medical discretion, 9. Known to the product; 10. Subject who is pregnant or lactating
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    A

    Phase A: subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).

    Drug: Methotrexate

  • Experimental
    B

    Phase B: will only start after 2nd or 3rd administration of phase A. Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).

    Drug: Methotrexate

  • Experimental
    C

    Phase C: will only start after 2nd or 3rd administration of phase B. Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).

    Drug: Methotrexate

Interventions

  • Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).

    Also known as: MTX-loaded nanoparticles

  • Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).

    Also known as: MTX-loaded nanoparticles

  • Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).

    Also known as: MTX-loaded nanoparticles

06

What researchers measure

Primary outcomes

  1. Change in clinical conditions

    Clinical condition will be measured by lung injuries

    Time frame: 21 days

Secondary outcomes

  1. Change of Clinical symptoms - respiratory rate

    Evaluation of Pneumonia change

    Time frame: 21 days

  2. Hypoxia

    oxygen saturation

    Time frame: 21 days

  3. Changes of blood oxygen

    PaO2 / FiO2 ratio

    Time frame: 21 days

  4. Inflammatory parameters

    C-reactive protein and ferritin

    Time frame: 21 days

  5. Evolution of Acute Respiratory Syndrome

    Time to wean off oxygen invasive ventilatory support

    Time frame: 21 days

  6. Hospital discharge

    Time to be discharged from hospital

    Time frame: 21 dyas

  7. ICU discharge

    Time to be discharged from ICU

    Time frame: 21 days

  8. Rate of mortality

    Evaluation of change in acute respiratory syndrome

    Time frame: 4 months

07

Study locations

1 site
  • Prevent Senior Private Operadora de Saúde LTDA.
    São Paulo, Brazil
    • Rodrigo Barbosa Esper · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2020; primary completion for Jun 2020, 1 month later.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 1 month is below that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2020
First posted
Apr 20, 2020
StartEst.
May 1, 2020
Primary completionEst.
Jun 30, 2020
CompletionEst.
Nov 30, 2020
Last update
Apr 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04352465
Lead sponsor
Azidus Brasil
Collaborators
InCor Heart Institute, Hospital Santa Marcelina, Prevent Senior Institute
Responsible party
Sponsor
First posted
Apr 20, 2020
Start date
May 1, 2020 (estimated)
Primary completion
Jun 30, 2020 (estimated)
Completion
Nov 30, 2020 (estimated)
Last update
Apr 29, 2020

Study contacts

Rodrido Esper, MD, PhD
Contact
dr.rodrigo.esper@preventsenior.com.br
+55 11 98179-7949
Luciana Ferrara
Contact
luciana.ferrara@azidusbrasil.com.br
+55 19 981428814

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion